FERNANDO

300K Solutions, is a biotech company committed to developing sustainable solutions

for storage of biological samples at room temperature.
The founders of 300K are a fully involved complementary senior executive team, who
have been working together for the last 12 years.
We are supported by a group of young, gender-balanced, and highly educated
professionals and partners.

PABLO

Annually, more than 40 million biological samples are stored worldwide in Ultra-low
temperature freezers in addition to the 2.000 M already frozen.
These figures indicate why this method is unsustainable. Firstly, because of its
high energy consumption, resulting in a significant CO2 footprint; and secondly,
because of the large amount of space that freezers require.
However, the major pain is the risk of losing the samples.
Now is the right time to disrupt the biospecimen storage market.

MARTA

Our technology is based on Freeze-drying, a process already established in the

pharma and food industries, but not suitable for biobanking activities. Until now.
300K has taken freeze-drying to a greater level of precision by holding several
proprietary patents that enable homogeneous high thermal transmission and accurate
pressure control. Besides this, and as trade secrets, we have formulated
stabilization excipients and customized freeze-drying cycles, adapted to each type
of biological sample, which have allowed us to transform sample aliquots into dry
products while preserving the original sample quality.
These innovations make our proposal the unique solution that solves all the
drawbacks associated with ultra-low temperature freezers.
Our technology reduces completely the use of refrigerants, decreases the CO2
indirectly produced for running freezers by 84%, and the energy consumption by 72%.

FERNANDO 2

126 potential customers have expressed their willingness to pay, and we have
already provided 3 quotations in Spain, UK, and Portugal. Besides that, several
companies have also shown their interest in using our technology.
Our solutions could be offered based on different business models, mainly depending
on the financial preferences of clients.
The scale-up potential is tremendous, since our technology could be implemented in
other target markets beyond biobanks.

FERNANDO 3

We are applying for the EIC accelerator grant, once we have validated our solution
in a relevant environment.
However, we need to demonstrate that it works as expected in an operational one,
thereby qualifying the system for pre-serial manufacturing.
We are also applying for equity to create our own European direct commercial
network and license our technology in the USA.

FERNANDO 4

Based on our previous demonstrated experience and track record, we will make the
company grow with a clear business plan, direction, and road maps.
The opportunity to transform the market is right now.
We have successfully done this before, and we will do it again.